New drug SKB571 targets advanced lung cancer in Mid-Stage trial
NCT ID NCT07230405
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a new drug called SKB571 in 295 people with advanced non-small cell lung cancer. The drug is given every three weeks to see if it can shrink tumors and how safe it is. The goal is to find a better treatment option for this serious disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SKB571
What this could lead to
If successful, this could point toward a new treatment option for advanced non-small cell lung cancer.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not confirm effectiveness. Side effects are possible and not yet fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NON-SMALL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-Sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••